According to a recent report from Global Market Insights Inc, the market is expected to achieve a valuation of USD 30.2 billion by 2032. This market which reached USD 22.2 billion in 2023, is projected to grow at a compound annual growth rate (CAGR) of 3.5% from 2024 to 2032. This growth is primarily driven by the rising incidence of hepatitis B and C infections and increasing awareness about these conditions.1
Key advancements in drug development, including antiviral therapies and immunotherapies, are enhancing patient care and further propelling market expansion. Improved diagnostic technologies, such as polymerase chain reaction (PCR) testing, have also contributed to early detection, increasing the demand for hepatitis treatments.1
Contagion works on spreading awareness about hepatitis c and b infections, in an interview with Danjuma Add, former president of the World Hepatitis Alliance he stated, “If we had increased investment, driven by political will and the commitment of funders, donors, and governments to domestic financing and healthcare systems, we could make significant progress. We would have programs to test more people, provide national treatment programs, and ensure access to services. The lack of commitment through financing is one of the major barriers to improving testing, diagnosis, and access to care for hepatitis patients.”2
3 Key Takeaways
- The global hepatitis treatment market is projected to grow from USD 22.2 billion in 2023 to USD 30.2 billion by 2032, with a compound annual growth rate of 3.5% driven by increasing hepatitis B and C infections.
- Key advancements in antiviral therapies and diagnostic technologies are enhancing patient care and increasing the demand for hepatitis treatments.
- The lack of funding and awareness remains a significant barrier to improving testing, diagnosis, and access to care for hepatitis patients, despite existing effective treatments and guidelines.
The market is categorized by disease type, treatment type, route of administration, and end-user. The hepatitis C segment was the largest contributor, generating USD 9.8 billion in 2023, thanks to rising infection rates and advancements in antiviral treatments. Antiviral drugs alone captured a significant market share of 61.4%, as they play a crucial role in managing hepatitis B and C by decreasing viral load and controlling disease progression.1
Oral administration of therapeutics is expected to be a significant market driver, projected to reach USD 12.1 billion by 2032 due to its convenience and high patient compliance. Healthcare providers, including hospitals and specialty clinics, will also contribute to growth at a CAGR of 3.5%, facilitating the administration of antiviral therapies and diagnostics.1
Current WHO Hepatitis B and C Treatment Guidelines
The guidelines will expand access to care and ensure more healthcare workers are trained and equipped to manage patients appropriately. We have the tools, we don’t need to reinvent anything about hepatitis prevention or treatment. Effective vaccines and treatments are available, but what is lacking is the funding and awareness to drive hepatitis elimination towards the 2030 goals.
Despite advances in infant vaccination, global birth-dose coverage is only 45% overall and 18% in Africa. Chronic Hepatitis B treatment remains underused, with only 13% diagnosed and 3% treated. New guidelines expand treatment criteria to include liver fibrosis, HBV DNA levels, co-infections, or abnormal ALT levels. They also introduce prophylaxis for HBsAg-positive pregnant women and emphasize improved testing, including point-of-care HBV DNA assays and universal HDV antibody testing.3
WHO recommends pan-genotypic direct-acting antivirals (DAAs) like sofosbuvir and daclatasvir for all chronic Hepatitis C patients, including children over 3. Treatment lasts 12 to 24 weeks and is now much cheaper in low- and middle-income countries, with prices under $50 in some areas. However, by the end of 2022, only about 20% of diagnosed patients had received DAAs.4
Regionally, the North American hepatitis treatment market is expected to reach USD 13.4 billion by 2032, driven by robust healthcare infrastructure and advancements in antiviral therapies. Europe, particularly the UK, is witnessing growth due to rising hepatitis cases and evolving treatment options, while the Asia-Pacific region is projected to expand at a CAGR of 4.1% through government-led hepatitis management programs.1
In summary, while the hepatitis treatment market is poised for significant growth, the journey toward effective management and elimination of hepatitis B and C requires action on funding, awareness, and healthcare provider training. By addressing these critical gaps, we can move closer to achieving the WHO’s ambitious goals for 2030 and improve the lives affected by these diseases.
References
